CervoMed to Participate in Upcoming Investor Conferences

Thu, 05 Mar 2026 07:30:00 -0500

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference
Format: 1x1 Investor Meetings
Date: Wednesday, March 11, 2026

38^th Annual ROTH Conference
Format: Fireside Chat & 1x1 Investor Meetings
Presentation Date: Monday, March 23, 2026
Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website

CervoMed to Participate in Upcoming Investor Conferences

Thu, 05 Mar 2026 07:30:00 -0500

Leerink Global Healthcare Conference
Format: 1x1 Investor Meetings
Date: Wednesday, March 11, 2026

38^th Annual ROTH Conference
Format: Fireside Chat & 1x1 Investor Meetings
Presentation Date: Monday, March 23, 2026
Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website

Form 8-K CervoMed Inc. For: Mar 04

Wed, 04 Mar 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260304/26111028.html

Form 8-K CervoMed Inc. For: Mar 04

Wed, 04 Mar 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260304/26111028.html

CervoMed selects dosing for Phase 3 dementia with Lewy bodies trial

Wed, 04 Mar 2026 07:30:25 -0500

CervoMed Inc. (NASDAQ: CRVO) announced it has selected a 50mg three times daily dosing regimen of neflamapimod for its planned Phase 3 trial in patients with dementia with Lewy bodies, according to a company statement.

The biotechnology company completed a Phase 1 study evaluating the pharmacokinetics of a new, stable crystal form of neflamapimod. The study aimed to address manufacturing variability issues that affected a previous Phase 2b trial.

The company reported that the pharmacokinetic profile of the new stable crystal form largely overlaps with the drug product used in the Phase 2b RewinD-LB trial extension, which demonstrated clinical activity. The 50mg

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Wed, 04 Mar 2026 07:30:00 -0500

Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process

Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension

To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial in dementia with Lewy bodies will be 50mg TID of the stable, crystal form of neflamapimod

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc.

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Wed, 04 Mar 2026 07:30:00 -0500

Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process

Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc.

Form 8-K CervoMed Inc. For: Feb 18

Wed, 18 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260218/26022391.html

Form 8-K CervoMed Inc. For: Feb 18

Wed, 18 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260218/26022391.html

CervoMed's neflamapimod selected for UK ALS trial platform

Wed, 18 Feb 2026 06:02:02 -0500

CervoMed Inc. (NASDAQ: CRVO) announced that its drug candidate neflamapimod has been selected for inclusion in the EXPERTS-ALS platform, a UK-based trial system designed to test potential treatments for amyotrophic lateral sclerosis.

The EXPERTS-ALS platform, funded by the UK National Institute for Health and Care Research and motor neuron disease charities, will evaluate neflamapimod in approximately 35 ALS participants over 18-24 weeks. The trial may expand to include up to 80 patients total. The first person with ALS is expected to receive the drug by the end of 2026.

The platform uses a randomized, multicenter, open-label trial design that measures the blood

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

Wed, 18 Feb 2026 06:00:00 -0500

Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models

UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026

Trial costs funded by United Kingdom government and leading motor neuron disease charities

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

Wed, 18 Feb 2026 06:00:00 -0500

Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models

UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026

Trial costs funded by United Kingdom government and leading motor neuron disease charities

CERo Therapeutics appoints Eric Francois to board of directors

Tue, 17 Feb 2026 08:00:17 -0500

CERo Therapeutics Holdings, Inc. (OTCQB: CERO) announced the appointment of Eric Francois to its board of directors, according to a company statement.

Francois brings over 25 years of life science industry experience to the cellular immunotherapy company. He spent 18 years as a senior banker with Raymond James, Credit Suisse, Lazard, and Cowen, providing board-level financial advice on transactions.

Previously, Francois served as Chief Financial Officer of SCYNEXIS (NASDAQ: SCYX), where he was responsible for raising over $300 million through equity, debt and non-dilutive sources. He also served as an independent director at CervoMed Inc. (NASDAQ: CRVO), where he coordinated efforts to

CERo Therapeutics appoints Eric Francois to board of directors

Tue, 17 Feb 2026 08:00:17 -0500

CERo Therapeutics Holdings, Inc. (OTCQB: CERO) announced the appointment of Eric Francois to its board of directors, according to a company statement.

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Tue, 17 Feb 2026 08:00:00 -0500

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company’s Board of Directors.

“Eric’s decades of financial, transactional and operational experience will make an immediate impact to CERo’s board of directors,” said Chris Ehrlich, Company Chairman and Chief Executive Officer. “Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development.”

Mr.

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Tue, 17 Feb 2026 08:00:00 -0500

Mr.

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Tue, 17 Feb 2026 08:00:00 -0500

Mr.

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Tue, 17 Feb 2026 08:00:00 -0500

Mr.

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Fri, 13 Feb 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260213/26001768.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Fri, 13 Feb 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260213/26001768.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Fri, 13 Feb 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260213/26001770.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Fri, 13 Feb 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260213/26001770.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: ELDER WILLIAM ROBERT

Fri, 13 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260213/26001751.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: ELDER WILLIAM ROBERT

Fri, 13 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260213/26001751.html

Form 4 CervoMed Inc. For: Feb 11 Filed by: Gregoire Sylvie

Fri, 13 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260213/26001760.html

StreetInsider.com News Articles

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences

Form 8-K CervoMed Inc. For: Mar 04

Form 8-K CervoMed Inc. For: Mar 04

CervoMed selects dosing for Phase 3 dementia with Lewy bodies trial

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Form 8-K CervoMed Inc. For: Feb 18

Form 8-K CervoMed Inc. For: Feb 18

CervoMed's neflamapimod selected for UK ALS trial platform

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

CERo Therapeutics appoints Eric Francois to board of directors

CERo Therapeutics appoints Eric Francois to board of directors

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Form 4 CervoMed Inc. For: Feb 11 Filed by: Winton Matthew

Form 4 CervoMed Inc. For: Feb 11 Filed by: ELDER WILLIAM ROBERT

Form 4 CervoMed Inc. For: Feb 11 Filed by: ELDER WILLIAM ROBERT

Form 4 CervoMed Inc. For: Feb 11 Filed by: Gregoire Sylvie